PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35280252-12	2021	Conclusion: This study is the first to show that the CYP4F2 rs2074900 SNP had a remarkable effect on ticagrelor PK, which is significant since it adds to the limited pharmacogenetic information on ticagrelor.	Ticagrelor	101-111	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	53-59	
35280252-12	2021	Conclusion: This study is the first to show that the CYP4F2 rs2074900 SNP had a remarkable effect on ticagrelor PK, which is significant since it adds to the limited pharmacogenetic information on ticagrelor.	Ticagrelor	197-207	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	53-59	
31124413-4	2019	CYP4F2 T allele significantly increased odds for bleeding in ticagrelor users (OR: 8.270, 95% CI: 3.917-17.462; p < 0.001).	Ticagrelor	61-71	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	0-6	
28604225-6	2017	CONCLUSION: Results of the current study showed that CYP4F2 rs3093135 TT variant carriers had a higher antiplatelet effect of ticagrelor, and more frequently had nonprocedural bleeding during ticagrelor therapy, as compared with AA and AT variant carriers.	Ticagrelor	126-136	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	53-59